SOLIGENIX, INC. Income Tax Examination, Penalties and Interest Expense
SOLIGENIX, INC. (SNGX) reported Income Tax Examination, Penalties and Interest Expense of $0 for the 12-month period ending 2013-12-31, per its 10-K filed 2014-03-26.
Discontinued › Expense Statement › Interest Expense
us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense · last filed 2014-03-26
- SOLIGENIX, INC. income tax examination, penalties and interest expense for fiscal 2013 was $0.00.
- SOLIGENIX, INC. income tax examination, penalties and interest expense for fiscal 2012 was $0.00.
- SOLIGENIX, INC. income tax examination, penalties and interest expense for fiscal 2011 was $0.00.
| Period end | Income Tax Examination, Penalties and Interest Expense 12 month |
|---|---|
| 2013-12-31 | $0.00 10-K · filed 2014-03-26 |
| 2012-12-31 | $0.00 10-K · filed 2014-03-26 |
| 2011-12-31 | $0.00 10-K · filed 2013-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |